Impact of discontinuing oxytocin in active labour on neonatal morbidity: an open-label, multicentre, randomised trial

What Was Tested

Researchers studied Oxytocin in this randomized controlled trial publication.

The researchers aimed to assess the impact of discontinuing oxytocin during active labour on neonatal morbidity.

Why It Was Studied

French Ministry of Health and the Département de la Recherche Clinique et du Développement de l'Assistance Publique-Hôpitaux de Paris.

Who Took Part

PubMed tags the participants as women only.

Participants who received oxytocin before 4 cm dilation were randomly assigned 1:1 to either discontinuous oxytocin (oxytocin infusion stopped beyond a cervical dilation equal to or greater than 6 cm) or continuous oxytocin (administration of oxytocin continued until delivery).

How the Study Was Run

The design is described as randomized, open-label and multicenter.

Random assignment meant chance, not the researchers, decided who got Oxytocin and who got the comparison, which limits bias.

Nothing was hidden in this open-label Oxytocin study: the participants and staff both knew the treatment.

More than one site took part, so the participants came from several places.

Randomisation was stratified by centre and parity.

This trial is registered with ClinicalTrials.gov, NCT03991091.

What Was Measured

Topics PubMed links to this paper include Oxytocin, Oxytocics, Labor, Induced, Labor, Obstetric and Morbidity.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Oxytocin.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Lancet (London, England)), a journal based in England.

More context: the Oxytocin compound page, all human trials.